Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.
Why do signaling proteins called interferons, which recruit the immune system to attack cancer cells, start helping the tumor grow rather than shrink when they linger too long?
